



Journal of Enzyme Inhibition and Medicinal Chemistry

ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: <https://www.tandfonline.com/loi/ienz20>

Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates

Ludovica Monti, Azzurra Stefanucci, Stefano Pieretti, Francesca Marzoli, Lorenzo Fianza, Adriano Mollica, Sako Mirzaie, Simone Carradori, Luciano De Petrocellis, Aniello Schiano Moriello, Sándor Benyhe, Ferenc Zádor, Edina Szűcs, Ferenc Ötvös, Anna I. Erdei, Reza Samavati, Szabolcs Dvorácskó, Csaba Tömböly & Ettore Novellino

To cite this article: Ludovica Monti, Azzurra Stefanucci, Stefano Pieretti, Francesca Marzoli, Lorenzo Fianza, Adriano Mollica, Sako Mirzaie, Simone Carradori, Luciano De Petrocellis, Aniello Schiano Moriello, Sándor Benyhe, Ferenc Zádor, Edina Szűcs, Ferenc Ötvös, Anna I. Erdei, Reza Samavati, Szabolcs Dvorácskó, Csaba Tömböly & Ettore Novellino (2016) Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 31:6, 1638-1647, DOI: [10.3109/14756366.2016.1160902](https://doi.org/10.3109/14756366.2016.1160902)

To link to this article: <https://doi.org/10.3109/14756366.2016.1160902>



View supplementary material [↗](#)



Published online: 11 Apr 2016.



Submit your article to this journal [↗](#)



Article views: 938



View Crossmark data [↗](#)



Citing articles: 6 View citing articles [↗](#)

RESEARCH ARTICLE

Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates

Ludovica Monti¹, Azzurra Stefanucci², Stefano Pieretti³, Francesca Marzoli³, Lorenzo Fidanza³, Adriano Mollica⁴, Sako Mirzaie⁵, Simone Carradori⁴, Luciano De Petrocellis⁶, Aniello Schiano Moriello⁶, Sándor Benyhe⁷, Ferenc Zádor⁷, Edina Szűcs⁷, Ferenc Ötvös⁷, Anna I. Erdei⁷, Reza Samavati⁷, Szabolcs Dvorácskó⁷, Csaba Tömböly⁷, and Ettore Novellino⁸

¹Dipartimento di Chimica e Tecnologia del Farmaco, Sapienza Università di Roma, Rome, Italy, ²Dipartimento di Chimica, Sapienza Università di Roma, Rome, Italy, ³Istituto Superiore di Sanità, Dipartimento del Farmaco, Rome, Italy, ⁴Dipartimento di Farmacia, Università di Chieti-Pescara "G. d'Annunzio", Chieti, Italy, ⁵Department of Biochemistry, Islamic Azad University, Sanandaj, Iran, ⁶Endocannabinoid Research Group, Institute of Biomolecular Chemistry, National Research Council, Naples, Italy, ⁷Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary, and ⁸Dipartimento di Farmacia, Università di Napoli "Federico II", Naples, Italy

Abstract

Fentanyl is a powerful opiate analgesic typically used for the treatment of severe and chronic pain, but its prescription is strongly limited by the well-documented side-effects. Different approaches have been applied to develop strong analgesic drugs with reduced pharmacologic side-effects. One of the most promising is the design of multitarget drugs. In this paper we report the synthesis, characterization and biological evaluation of twelve new 4-anilidopiperidine (fentanyl analogues). *In vivo* hot-Plate test, shows a moderate antinociceptive activity for compounds **OMDM585** and **OMDM586**, despite the weak binding affinity on both μ and δ -opioid receptors. A strong inverse agonist activity in the GTP-binding assay was revealed suggesting the involvement of alternative systems in the brain. Fatty acid amide hydrolase inhibition was evaluated, together with binding assays of cannabinoid receptors. We can conclude that compounds **OMDM585** and **586** are capable to elicit antinociception due to their multitarget activity on different systems involved in pain modulation.

Keywords

Fentanyl, FAAH enzyme, MAGL enzyme, opioids, pain

History

Received 3 February 2016
Revised 25 February 2016
Accepted 26 February 2016
Published online 11 April 2016

Introduction

Opioids have been used for years in the control of pain from moderate to severe, and with controversial results especially in the management of chronic and neuropathic pain.

Addiction and tolerance, including nausea and vomiting, constipation and respiratory depression are well known adverse side effects¹. Fentanyl is the prototype of the 4-anilidopiperidines opioid analgesics and is characterized by high potency and efficacy. Expansion of the structure-activity relationships (SAR) of fentanyl derivatives has led to the discovery of new morphinomimetics with diverse pharmacological profiles². Numerous research groups have studied the structure's modifications of fentanyl, with the aim to reduce the pharmacologic side effects, acting on other opioid receptors such as the δ -receptor³. It has been demonstrated that μ and δ -opioid receptors form heterodimers and their simultaneous stimulation can give a better antinociceptive activity⁴. Fentanyl has been previously

employed in the design of bivalent drugs by Hruby et al.⁵ in light of the well-documented interaction between opioid and cannabinoid receptors⁶.

Stimulated by the previously described SAR on fentanyl and its bivalent analogues, which reported no general rules for the effect of the substitution on the propionyl amide moiety,⁵ we synthesised 12 novel 4-anilidopiperidine derivatives replacing the tertiary propyl-amide group in fentanyl, with different aryl-ureas and aryl-carbamates found in several active FAAH and MAGL inhibitors with the intent to develop novel multitarget analgesics.^{7,8} FAAH and MAGL are hydrolase enzymes, responsible of the endocannabinoid cleavage, and their inhibitors have shown to possess nociceptive effects in different pain models, as a consequence of the increased level of endocannabinoids^{9,10}.

A first series of compounds bearing the 4-anilidopiperidine scaffold on fentanyl was synthesised, and several substituted *O*-arylcabamates (compounds **OMDM584–OMDM589**) have been used in place of the propylamide function. A second series of *N*-arylureas was designed replacing the *N*-propyl moiety of fentanyl with several substituted *N*-aryl building blocks (compounds **OMDM590–OMDM595**). The synthesis of all compounds is depicted in [Scheme 1](#), structural features are reported in [Table 1](#).

Address for correspondence: Adriano Mollica, Dipartimento di Scienze del Farmaco, Faculty of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini, 31, 66100 Chieti, Italy. Tel: +39-0871-3554476. E-mail: a.mollica@unich.it

Scheme 1. Reagents and conditions: (a) 1-phenethyl-*N*-phenylpiperidin-4-amine (0.5 mmol), Et₃N (0.6 mmol), DCM, r.t. overnight.




Table 1. Structures and yields of products **OMDM584–595**.

Products	X	Y	Yields	Products	X	Y	Yields
OMDM584	O		80%	OMDM590	NH		31%
OMDM585	O		63%	OMDM591	NH		61%
OMDM586	O		51%	OMDM592	NH		48%
OMDM587	O		80%	OMDM593	NH		79%
OMDM588	O		26%	OMDM594	NH		74%
OMDM589	O		13%	OMDM595	NH		79%

Results and discussion

Chemistry

Carbamates **OMDM584–589** were synthesised starting from the corresponding chloroformate intermediate, which was prepared using phosgene in toluene with the appropriate substituted phenol and triethylamine (Scheme 1).

The so obtained chloroformate was reacted with a solution of 1-phenethyl-*N*-phenylpiperidin-4-amine in DCM in presence of triethylamine at room temperature, to yield the desired crude product. In the same way, ureas **OMDM590–595** were obtained from the corresponding urethane intermediates, which were prepared using phosgene in toluene with the appropriate substituted anilines and triethylamine (Scheme 1).

Then urethane intermediate was reacted with a solution of 1-phenethyl-*N*-phenylpiperidin-4-amine in DCM in presence of triethylamine at room temperature, to yield the desired crude product.

All crude compounds were purified on silica gel chromatography to give final products in good yields (Table 1).

In vitro assay

Biological *in vitro* tests were performed on all products, for μ and δ -opioid receptor affinity, on FAAH and MAGL (Table 2).

Receptor binding assays

Competition binding experiments

In competition binding experiments, fentanyl reduced the [³H] DAMGO specific binding on μ -opioid receptor (MOR) with a very low 5.99 nM IC₅₀ value, indicating a high affinity for MOR (Figure S1), as expected from previous reports, confirming the adequate performance of the radioligand¹¹.

The fentanyl analogues showed a wide range of affinity for MOR from mid nanomolar (IC₅₀ > ~500 nM) to micromolar (IC₅₀ < ~20 μ M) (Figure S1) concentration. Compounds **OMDM586**, **591–593** showed the highest affinity for MOR with mid nanomolar IC₅₀ values. Thus among the structural modifications of fentanyl, the combination of the amide group in position X with 4-, 3-chlorophenyl and 4-*tert*-butylphenyl groups in position Y (**OMDM591–593**) gives good affinity (Table 3).

Since compounds **OMDM585** and **586** showed analgesic activities in pharmacological assays, we further characterized their binding for δ -opioid receptor (DOR), κ -opioid receptor (KOR) and cannabinoid receptors (CBR), again in competition binding assays (Figure S2). Both compounds reduced total specific binding of the KOR selective [³H]U-69593 and DOR selective [³H]IleDelt II with an IC₅₀ value in the micromolar

range, showing poor affinity for these two opioid receptors (Fig S2A and B). In case of [³H]WIN55212–2 binding experiments, the affinity of **OMDM585** and **586** was weaker for CBR, since it decreased [³H]WIN55212–2 specific binding by about 20–30% with an IC₅₀ value in the micromolar range (Figure S2D, Table S1). For comparison the unlabelled forms of the tritiated ligands reported IC₅₀ values in the nanomolar range, indicating that the radioligands performed adequately (Figure S2, Table S1).

[³⁵S]GTP γ S binding experiments

In G-protein activity stimulation measurements with [³⁵S]GTP γ S binding tests, fentanyl activated G-protein stimulation with a maximum efficacy of 159.8% (nearly 60% above basal activity) and with a potency of 110.4 nM (Table S2, Figure S3A and C), which corresponds with previous studies¹¹.

Interestingly, all fentanyl analogues showed inverse agonist properties, since they reduced G-protein basal activity with very similar parameters: the maximum efficacy was between ~80–100%, and their potency was between ~3–5 μ M (Figure S3A and C, Table S2). This effect however was not opioid receptor mediated, since it could not be reversed by the antagonist naloxone even in high, 10 μ M concentrations, resulting in very similar maximum efficacy and potency values to those in the absence of naloxone (Figure S3B and D, Table S2). For comparison, the activity of fentanyl was markedly inhibited in the presence of naloxone and the G-protein activity reduced back to basal activity level (Figure S3B and D, Table S2). The inverse agonist properties of the fentanyl analogues are most probably due to the introduction of the benzene ring in position X, since this is shared by all analogues, but not by fentanyl (Scheme 1). In fact, the benzene ring together with the piperidine ring is also shared by rimonabant, which is an inverse agonist on CB₁ receptor¹². However, the inverse agonist effect of rimonabant can be also mediated by a yet unidentified pertussis toxin sensitive GPCR.¹³

Additionally, the fentanyl analogues described in this study also share some elements of the pharmacophore of other CB₁ receptor inverse agonists, such as the two aromatic moieties, a hydrogen acceptor unit and a cyclic lipophilic part.¹⁴

In vivo assays

Hot-Plate test was performed on all compounds to study the influence of different pharmacological properties on their analgesic profile. Results are shown in Figure 1.

Hot-plate data confirm that compounds **OMDM585**, **586** have a good analgesic activity only at high doses. However, this cannot be explained by the opioid activity, as the binding to μ and δ -opioid receptors is very weak, furthermore the FAAH and MAGL inhibition activity was negligible.

The inverse agonist activity on the G-Protein stimulation leaves us with the hypothesis that products **OMDM585** and **586** are able to elicit their antinociceptive activity either by interaction to block one or more excitatory circuits in the brain rather than by their affinity to μ opioid and cannabinoid receptors at micromolar range.







Molecular docking

According to the experimental results, the inactive state of μ -opioid receptor was used for docking (PDB code: 4dkl). The lowest docking energy poses of the analogues only partly matched with the docked pose of fentanyl¹⁵, as shown in Table S3. Furthermore, because the analogues reported weak binding affinity and the agonist character of the parent molecule fentanyl changed, it is feasible to assume that their binding mode differs from that of fentanyl. To check this assumption, a distance based

Table 2. *In vitro* assays on FAAH and MAGL inhibition.

Compounds	IC ₅₀ on FAAH μ M	FAAH Max inhibition at 10 μ M	IC ₅₀ on MAGL μ M	MAGL Max inhibition at 10 μ M
OMDM 584	>10	0%	>10	0%
OMDM 585	>10	0%	>10	0%
OMDM 586	>10	1.90%	>10	0%
OMDM 587	>10	10.2%	>10	0.74%
OMDM 588	>10	7.40%	>10	0%
OMDM 589	>10	7.40%	>10	0.41%
OMDM 590	>10	7.25%	>10	0%
OMDM 591	>10	8.26%	>10	3.50%
OMDM 592	>10	9.76%	>10	7.32%
OMDM 593	>10	5.82%	>10	1.28%
OMDM 594	>10	7.49%	>10	0%
OMDM 595	>10	9.16%	>10	2.97%

Table 3. The affinity values ($\log IC_{50} \pm SEM.$) of **OMDM584–595** compounds and fentanyl in [3H]DAMGO competition binding assays in rat brain membrane homogenates. The $\log IC_{50}$ values were calculated according to the competition binding curves (see Supplementary Figure 1S). for better comparison the two different basic structures are presented side by side.

Compounds	$\log IC_{50} \pm S.E.M. (M) (IC_{50})$		Compounds	
	Fentanyl			
	–8.22 \pm 0.06 (5.99 nM)		Fentanyl	
	X			
Y	O	N		
	OMDM 584	–5.84 \pm 0.04 (1442 nM)	–6.28 \pm 0.06 ^{###} (516.8 nM)	OMDM 590
	OMDM 585	–5.66 \pm 0.1 (2180 nM)	–6.17 \pm 0.06 ^{##} (665.1 nM)	OMDM 591
	OMDM 586	–6.18 \pm 0.06 (654.2 nM)	–6.18 \pm 0.04 (658.9 nM)	OMDM 592
	OMDM 587	–5.73 \pm 0.33 (1830 nM)	–4.63 \pm 0.24 [*] (23050 nM)	OMDM 593
	OMDM 588	–5.57 \pm 0.10 (2657 nM)	–5.39 \pm 0.13 [*] (4031 nM)	OMDM 594
	OMDM 589	–5.38 \pm 0.1 [*] (4093 nM)	–6.91 \pm 0.05 [*] (1204 nM)	OMDM 595

“X” and “Y” indicates the chemical modifications performed in the basic structure of fentanyl (Scheme 1). Compounds with comparable lower affinity within the fentanyl analogues are highlighted in bold.

#Indicates the significant difference between the analogues with oxygen atom and an amide group in position X (Figure 1B and C) within the corresponding substitution in position Y (Figure 1). ^{###} $p < 0.001$; ^{##} $p < 0.01$ (unpaired t -test with two-tailed p value).

*Indicates the significant difference compared to the compounds in bold within the analogues with oxygen heteroatom or amid group in the position X.

interaction model was matched against the docking energies. The interaction model was constructed as follows: the distances between selected atoms of the ligands and the receptor were measured, and the square root of the sum of the squares of the Pairwise Distances was used as a measure of binding distance, as shown in Equation 1.

$$\sqrt{\sum_i [d(l_i, r_i)]^2} \quad (1)$$

Where, $d(l_i, r_i)$ is the distance between the i^{th} selected atom of the ligand (l_i) and the receptor (r_i), respectively. The

corresponding atom pairs are shown in Table S4. The docked pose, possessing the minimum binding distance by the above formula, was selected for each ligand and the corresponding ligand efficiency and distance values were used to fit a linear regression model (Figure 2).

The Spearman rank correlation coefficients were calculated too. All atom pair combinations were checked to qualify the different interaction (binding) modes. The interaction models based on the previously published docking pose (Table S4, column A for ligand atoms), in which the anilide ring points toward the extracellular direction,¹⁵ resulted in very weak

regression models and mainly with negative slope. The negative slope is contradictory to the expectations that the deeper binding energy is a consequence of the shorter binding distance. This gave rise the possibility that the orientation of the bound analogues differ from that of fentanyl which can also be seen in Table S3.

To check this assumption, interaction models with the opposite orientation were tested (Table S4, column B for ligand atoms). This type of interaction models resulted in higher correlation between the ligand efficiencies and the calculated distances. The best model is shown in Figure S4.

The key amino acids interactions are (i) Asp147-proton on piperidine N, (ii) Tyr326 side chain-anilide aromatic ring, (iii) Ile144 side chain-phenethyl aromatic ring (Figure 3).

These results are in agreement with the finding that there are more sites to accommodate the analogues with the additional large substituent within the binding pocket in the orientation opposite to the literature pose of fentanyl. Comparing the different interaction models (atom pair combinations), the best linear fit was obtained with two atom pairs, 1 and 2 (Table S4). Involving any other interactions significantly decreased the linear fit, except





Figure 1. *In vivo* activity of compounds **OMDM584–595** by hot-Plate test. Data from hot plate experiments. **** is for $p < 0.001$ versus Vehicle; ** is for $p < 0.01$ versus Vehicle; * is for $p < 0.05$ versus Vehicle. $N = 10$.



in the case of the non-fentanyl-like orientation, for which the 1–2–3 interactions resulted in almost the same regression (Figure 2, $r^2 = 0.741$, Spearman's rank correlation: 0.758).

The interaction modes of fentanyl analogues are shown in supplementary Figure (Figure S4). The most important interaction between the synthesized analogues and MOR is a hydrophobic interaction. Compound **OMDM584** interacts just with Tyr148 due to π - π stacking. **OMDM585** can be stable in the binding site of MOR (Tyr128, Trp293 and Tyr326) via three π - π stacking interactions. However, the presence of some polar or charged residues in proximity of Fentanyl analogues may affect the MOR activation. The presence of Lys303 and Lys233, as the positive charged residues, in the vicinity of *tert*-butylphenyl moiety of **OMDM587** can dramatically destabilize the protein:ligand complex. The same cases can be found for the other fentanyl analogues: Asp147 and Lys233 are located in the vicinity of phenyl and chlorophenyl moieties of **OMDM585**. Also, in the case of **OMDM586**, Lys233, Glu229 and Asn230 can have negative effects on MOR:ligand complex stability. In the active form of MOR, Tyr148 can participate in the hydrogen bonding network involving Lys233 and a water molecule. This study reported that the ionic interaction between ligand and Asp147 has been found in either active or inactive form of MOR. Based on our docking results, no similar interaction was found for fentanyl analogues.




Figure 3. Definition of interactions; on the left: orientation similar to that reported by Micovic et al.¹⁵ on the right: opposite orientation.




Figure 2. Linear regression for the best interaction model of compounds **OMDM584–595**.

Conclusions

Potential abuse, unwanted side effects and lack of analgesic efficacy are major problems in prescribing opioid analgesics¹⁶.

Bi- or poly-functional compounds can fight chronic and neuropathic pain at various levels, demonstrating some ability to cross the BBB, with reduced or none sign of tolerance and addiction, thus supporting the idea that a single drug with FAAH/MAGL inhibitor activity plus an opioid agonist activity, could be a very attractive design for the development of a “third generation” painkillers⁶.

In this study, we investigated the potential of multi-target compounds combining opioid agonists and FAAH/MAGL inhibitors. The pharmacological profile of such compounds should join high efficacy in chronic pain states reducing the development of tolerance. Significant advantages over a multidrug approach could be: (i) oral administration, (ii) better pharmacokinetic properties, (iii) no drug–drug interactions and (iv) improved compartment targeting¹⁷.

The data obtained so far, indicate that our products have weak affinity for μ -opioid receptors, and are not strong inhibitors of FAAH/MAGL. However, two products revealed a good antinociceptive activity but very weak potency when compared to fentanyl, therefore we concluded that the activity wasn't mediated by the opioid system or endocannabinoids. In our studies, a strong inverse agonist activity in the stimulation of the G_{o/i} protein was revealed, which can be related to several systems present in the brain, directly involved in pain modulation.

A direct binding to CB1 receptor has been explored, but the so obtained data are in accord with the observed activity.

Further, *in silico* molecular docking studies have been performed and definitely ruled out the involvement of the known systems in the antinociceptive activity. The comparison of the best regression model for the conventional, fentanyl-like orientation and the opposite one indicates that the latter is more feasible. It suggests that the analogues may recognise MOR in a different manner than fentanyl, due to the size of the new substituents.

Based on these results, the most important interactions between the ligands and the receptor are (i) Asp147-proton on piperidine N, (ii) Tyr326 side chain-anilide aromatic ring, (iii) Ile144 side chain-phenethyl aromatic ring. This is in agreement with the experimental results showing that the analogues lost the agonistic character.

We may conclude that the pharmacologic profile observed in the murine tests may be explained by the modulation of several receptors in the brain, related to the stimulation of the cerebral activity and usually responsible for enhancing the noxious stimuli, like adrenergic, glutamergic, substance P and others. Although it has been previously reported that the fentanyl analgesic activity could be readily maintained into small multitarget ligands, the incorporation of potent endocannabinoid activity is more intriguing and challenging¹⁸.

Further studies are currently underway in our laboratories to design multitarget molecules with potent inhibitory activity at FAAH enzyme and as strong opioid agonists.

Experimental section

Material and methods

All chemical reagents were commercially available unless otherwise indicated. TLC was performed by using Merck F254 silica plates (Kenilworth, NJ) and components were analyzed by using UV light and an iodine chamber. Melting points were determined on a Buchi apparatus and are uncorrected. Column chromatographies were carried out using Merck silica gel 60 (230–400 mesh). IR spectra were recorded on a Spectrum-One FT-ATR

spectrometer (Perkin-Elmer, Waltham, MA). Band position and absorption ranges are given in cm^{-1} . ¹H and ¹³C NMR spectra were obtained on a Bruker Avance 400 MHz (Pittsburgh, PA), using CDCl₃ as solvent.

Chemistry

Synthetic procedure for the carbamates OMDM584–589

To a stirred 15% phosgene solution in toluene (3.3 mL, 5 mmol) a solution of the appropriately-substituted phenol (1.0 mmol) and Et₃N (0.168 mL, 1.2 mmol) in dry toluene (5 mL) was added dropwise at 0 °C. The reaction mixture was stirred for 3 h at room temperature and evaporated under vacuum. The crude chloroformate was dissolved in dry DCM (4 mL) and a solution of 1-phenethyl-*N*-phenylpiperidin-4-amine (0.140 g, 0.50 mmol) and Et₃N (0.084 mL, 0.6 mmol) in dry DCM (2 mL) was added dropwise at room temperature with stirring. The reaction mixture was stirred overnight at room temperature, diluted with water, and extracted with AcOEt. The organic phase was washed with NaHCO₃ s.s. and twice with water, dried (Na₂SO₄), and evaporated under vacuum. The residue was purified by column chromatography.

Phenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (584)

Yield 80% (hexane/AcOEt, 7:3 as chromatographic eluent); mp 138–139 °C (from hexane/CH₂Cl₂); IR 2952, 2763, 1716, 1595, 1494, 1320, 1199, 1032, 991 cm^{-1} ; ¹H NMR (400 MHz) δ 1.59 (2H, m), 1.94 (2H, m), 2.15 (2H, m), 2.55 (2H, m), 2.74 (2H, m), 3.04 (2H, d, *J* = 11.6 Hz), 4.33 (1H, m), 7.12–7.34 (15H, m); ¹³C NMR (100 MHz) δ 30.79, 33.84, 53.04, 56.45, 60.41, 121.61, 125.18, 126.06, 127.92, 128.39, 128.63, 128.94, 129.10, 129.99, 137.73, 140.17, 151.36, 154.07. HRMS (ESI-MS, 140 eV): *m/z* [M + H]⁺ calculated for C₂₆H₂₉N₂O₂⁺: 401.2151, found: 401.2168.

4-Chlorophenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (585)

Yield 63% (hexane/AcOEt, 7:3 as chromatographic eluent); mp 134–135 °C (from hexane/CH₂Cl₂); IR 2951, 2764, 1714, 1595, 1488, 1319, 1210, 1089, 996 cm^{-1} ; ¹H NMR (300 MHz) δ 1.58 (2H, m), 1.94 (2H, m), 2.14 (2H, m), 2.54 (2H, m), 2.73 (2H, m), 3.03 (2H, d, *J* = 11.7 Hz), 4.31 (1H, m), 6.96–7.41 (14H, m); ¹³C NMR (75 MHz) δ 30.82, 33.87, 53.02, 55.65, 60.39, 122.96, 126.04, 128.02, 128.38, 128.61, 128.98, 129.08, 129.89, 130.44, 137.56, 140.18, 149.88, 153.62. HRMS (ESI-MS, 140 eV): *m/z* [M + H]⁺ calculated for C₂₆H₂₈ClN₂O₂⁺: 435.1761, found: 435.1765.

3-Chlorophenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (586)

Yield 51% (hexane/AcOEt, 75:25 as chromatographic eluent); mp 96–97 °C (from hexane/CH₂Cl₂); IR 2949, 2760, 1717, 1589, 1493, 1299, 1203, 1020, 993 cm^{-1} ; ¹H NMR (300 MHz) δ 1.58 (2H, m), 1.95 (2H, m), 2.14 (2H, m), 2.55 (2H, m), 2.73 (2H, m), 3.04 (2H, d, *J* = 11.7 Hz), 4.30 (1H, m), 6.94–7.41 (14H, m); ¹³C NMR (75 MHz) δ 30.78, 33.86, 53.01, 55.70, 60.38, 109.97, 119.98, 122.23, 125.40, 126.04, 128.05, 128.37, 128.61, 128.99, 129.77, 129.86, 134.30, 140.17, 151.85, 153.42. HRMS (ESI-MS, 140 eV): *m/z* [M + H]⁺ calculated for C₂₆H₂₈ClN₂O₂⁺: 435.1761, found: 435.1765.

4-(tert-Butyl)phenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (587)

Yield 80% (hexane/AcOEt, 75:25 as chromatographic eluent); mp 152–154 °C (from hexane/CH₂Cl₂); IR 2944, 2795, 1710, 1597,

1494, 1292, 1223, 1022, 998 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.27 (9H, s), 1.60 (2H, m), 1.95 (2H, m), 2.14 (2H, m), 2.54 (2H, m), 2.73 (2H, m), 3.03 (2H, d, $J = 11.1$ Hz), 4.32 (1H, m), 6.95 (2H, d, $J = 7.5$ Hz), 7.14–7.39 (12H, m); ^{13}C NMR (75 MHz) δ 30.85, 31.39, 33.87, 34.34, 53.07, 55.48, 60.41, 120.83, 125.97, 126.02, 127.79, 128.36, 128.61, 128.86, 129.98, 137.87, 140.22, 147.89, 149.02, 154.19. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{30}\text{H}_{37}\text{N}_2\text{O}_2^+$: 457.2777, found: 457.2781.

4-(Trifluoromethyl)phenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (588)

Yield 26% (hexane/AcOEt, 7:3 as chromatographic eluent); mp 132–134 °C (from hexane/ CH_2Cl_2); IR 2946, 2790, 1709, 1598, 1497, 1305, 1214, 1126, 1065, 995 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.60 (2H, m), 1.95 (2H, m), 2.15 (2H, m), 2.55 (2H, m), 2.74 (2H, m), 3.04 (2H, d, $J = 11.4$ Hz), 4.32 (1H, m), 7.14–7.42 (12H, m), 7.56 (2H, d, $J = 8.1$ Hz); ^{13}C NMR (75 MHz) δ 30.77, 33.86, 53.00, 55.76, 60.38, 121.92, 126.06, 126.44 (q, $J = 36.75$ Hz), 128.14, 128.39, 128.62, 129.05, 129.84, 137.43, 140.16, 153.20, 153.91. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{28}\text{F}_3\text{N}_2\text{O}_2^+$: 469.2025, found: 469.2023.

3-(Trifluoromethyl)phenyl(1-phenethylpiperidin-4-yl)(phenyl)carbamate (589)

Yield 13% (hexane/AcOEt, 7:3 as chromatographic eluent); mp 88–90 °C (from hexane/ CH_2Cl_2); IR 2951, 2786, 1718, 1597, 1496, 1278, 1206, 1161, 1030, 995 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.60 (2H, m), 1.95 (2H, m), 2.15 (2H, m), 2.55 (2H, m), 2.74 (2H, m), 3.04 (2H, d, $J = 11.7$ Hz), 4.32 (1H, m), 7.15–7.41 (14H, m); ^{13}C NMR (75 MHz) δ 30.77, 33.876, 53.01, 55.78, 60.39, 118.90, 121.95, 125.22, 126.06, 128.14, 128.39, 128.62, 129.06, 129.61, 129.86, 131.37, 131.80, 137.41, 140.17, 151.42, 153.38. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{28}\text{ClN}_2\text{O}_2^+$: 435.1761, found: 435.1765.

General procedure for the synthesis of ureas OMDM590–595

To a stirred 15% phosgene solution in toluene (3.3 mL, 5 mmol) a solution of the appropriate aniline (1.0 mmol) and Et_3N (0.35 mL, 2.5 mmol) in dry toluene (5 mL) was added drop-wise at 0 °C. The reaction mixture was stirred for 3 h at room temperature and evaporated under vacuum. The residue of the crude urethane was dissolved in dry toluene (4 mL) and a solution of 1-phenethyl-*N*-phenylpiperidin-4-amine (0.140 g, 0.50 mmol) in dry toluene (2 mL) was added drop-wise at room temperature with stirring. The reaction mixture was stirred overnight at room temperature, diluted with water, and extracted with AcOEt. The organic phase was washed with NaHCO_3 s.s. and twice with water, dried (Na_2SO_4), and evaporated under vacuum. The residue was purified by column chromatography.

1-(1-Phenethylpiperidin-4-yl)-1,3-diphenylurea (590)

Yield 31% (hexane/AcOEt, 4:6 as chromatographic eluent); mp 152–155 °C (from hexane/ CH_2Cl_2); IR 3426, 2922, 2758, 1674, 1519, 1490, 1437, 1313, 1282, 1079 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.48 (2H, m), 1.90 (2H, m), 2.18 (2H, m), 2.55 (2H, m), 2.73 (2H, m), 3.00 (2H, d, $J = 11.4$ Hz), 4.60 (1H, m), 5.86 (1H, s), 6.94–7.49 (15H, m); ^{13}C NMR (75 MHz) δ 31.12, 33.85, 52.77, 53.16, 60.46, 119.19, 122.77, 125.99, 128.35, 128.60, 128.71, 128.99, 130.01, 131.27, 137.23, 138.88, 140.21, 154.10. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{29}\text{N}_3\text{O}^+$: 399.2232, found: 399.2251.

3-(4-Chlorophenyl)-1-(1-phenethylpiperidin-4-yl)-1-phenylurea (591)

Yield 61% (hexane/AcOEt, 6:4 as chromatographic eluent); mp 163–165 °C (from hexane/ CH_2Cl_2); IR 3406, 2944, 2762, 1666, 1504, 1491, 1395, 1304, 1232, 1088 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.46 (2H, m), 1.89 (2H, m), 2.17 (2H, m), 2.54 (2H, m), 2.73 (2H, m), 3.02 (2H, d, $J = 11.4$ Hz), 4.58 (1H, m), 5.86 (1H, s), 7.14–7.51 (14H, m); ^{13}C NMR (75 MHz) δ 31.10, 33.87, 52.92, 53.15, 60.46, 120.42, 126.02, 127.67, 128.37, 128.61, 128.66, 129.15, 130.10, 131.22, 137.02, 137.53, 140.20, 153.91. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{28}\text{ClN}_3\text{O}^+$: 433.1843, found: 433.1849.

3-(3-Chlorophenyl)-1-(1-phenethylpiperidin-4-yl)-1-phenylurea (592)

Yield 48% (CHCl_3 /AcOEt, 8:2 as chromatographic eluent); mp 164–166 °C (from hexane/ CH_2Cl_2); IR 3282, 2923, 2769, 1638, 1587, 1513, 1426, 1306, 1242, 1084 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.48 (2H, m), 1.90 (2H, m), 2.18 (2H, m), 2.55 (2H, m), 2.73 (2H, m), 3.03 (2H, d, $J = 11.4$ Hz), 4.56 (1H, m), 5.88 (1H, s), 6.92–7.49 (14H, m); ^{13}C NMR (75 MHz) δ 31.06, 33.84, 52.97, 53.14, 60.44, 117.09, 119.15, 122.76, 126.04, 128.38, 128.62, 129.23, 129.67, 130.15, 131.17, 136.92, 140.11, 140.19, 153.76. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{26}\text{H}_{28}\text{ClN}_3\text{O}^+$: 433.1843, found: 433.1849.

3-(4-(tert-Butyl)phenyl)-1-(1-phenethylpiperidin-4-yl)-1-phenylurea (593)

Yield 79% (CH_2Cl_2 /AcOEt, 7:3 as chromatographic eluent); mp 168–170 °C (from hexane/ CH_2Cl_2); IR 3415, 2958, 1670, 1588, 1511, 1405, 1322, 1283, 1236, 1083 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.26 (9H, s), 1.45 (2H, m), 1.88 (2H, m), 2.18 (2H, m), 2.55 (2H, m), 2.73 (2H, m), 3.02 (2H, d, $J = 11.1$ Hz), 4.59 (1H, m), 5.79 (1H, s), 7.13–7.49 (14H, m); ^{13}C NMR (75 MHz) δ 31.15, 31.37, 33.88, 34.17, 52.74, 53.20, 60.50, 119.09, 125.54, 126.01, 128.36, 128.62, 128.93, 129.97, 131.32, 136.24, 137.38, 140.25, 145.74, 154.30. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{30}\text{H}_{37}\text{ClN}_3\text{O}^+$: 455.2858, found: 455.2867.

1-(1-Phenethylpiperidin-4-yl)-1-phenyl-3-(4-(trifluoromethyl)phenyl)urea (594)

Yield 74% (CH_2Cl_2 /AcOEt, 7:3 as chromatographic eluent); mp 182–184 °C (from hexane/ CH_2Cl_2); IR 3400, 2954, 2803, 1671, 1594, 1509, 1408, 1317, 1235, 1116, 1076 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.50 (2H, m), 1.90 (2H, m), 2.18 (2H, m), 2.55 (2H, m), 2.74 (2H, m), 3.03 (2H, d, $J = 11.4$ Hz), 4.56 (1H, m), 6.03 (1H, s), 7.15–7.51 (14H, m); ^{13}C NMR (75 MHz) δ 31.07, 33.88, 53.05, 53.13, 60.46, 118.44, 125.92, 125.98, 126.05, 128.39, 128.62, 129.32, 130.21, 131.15, 136.84, 140.20, 142.07, 153.61. HRMS (ESI-MS, 140 eV): m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{27}\text{H}_{28}\text{F}_3\text{N}_3\text{O}^+$: 467.2106, found: 467.2116.

1-(1-Phenethylpiperidin-4-yl)-1-phenyl-3-(3-(trifluoromethyl)phenyl)urea (595)

Yield 79% (CH_2Cl_2 /AcOEt, 7:3 as chromatographic eluent); mp 111–112 °C (from hexane/ CH_2Cl_2); IR 3419, 2949, 2805, 1668, 1526, 1491, 1336, 1277, 1116, 1097 $\text{csup}>/\text{sup}>$; ^1H NMR (300 MHz) δ 1.46 (2H, m), 1.90 (2H, m), 2.18 (2H, m), 2.55 (2H, m), 2.74 (2H, m), 3.03 (2H, d, $J = 11.4$ Hz), 4.59 (1H, m), 5.99 (1H, s), 7.14–7.59 (14H, m); ^{13}C NMR (75 MHz) δ 31.09, 33.89, 53.06, 53.16, 60.47, 115.82, 119.27, 122.20, 126.046, 128.39, 128.63, 129.16, 129.31, 130.21, 131.18, 131.36, 136.86, 139.47,

140.21, 153.81. HRMS (ESI-MS, 140 eV): m/z $[M+H]^+$ calculated for $C_{27}H_{28}F_3N_3O^+$: 467.2106, found: 467.2116.

Molecular docking

Fentanyl and its analogues were docked to the X-ray structure of the mouse μ -opioid receptor in inactive state obtained from the protein structure repository (PDB code: 4dkl, <http://www.rcsb.org>). Missing residues of the receptor were restored by the MODELLER programme package¹⁹.

Docking the flexible ligands to rigid receptor model was performed by AutoDock Vina²⁰, and AutoDockTools²¹, using the default system setup. The size of the docking grid box was 55 Å, centered on residue Asp147. The ligand structures were drawn at pH 7.4 and energy minimized by Avogadro²², using the MMFF94s molecular force field.

For visualization VMD²³, AutoDockTools, PMV and MSMS²⁴, program packages were used.

Data analysis was performed by R²⁵, and linux bash scripts. All calculations were performed in linux environment (Ubuntu Oneiric). To compare the binding ability of the fentanyl analogues, the ‘‘ligand efficiency’’ values were used by dividing the docking energy by the number of non-hydrogen atoms of the molecule.

In vitro biological assays

Chemicals

Tris-HCl, EGTA, NaCl, $MgCl_2 \times 6H_2O$, GDP, the GTP analogue GTP γ S, fentanyl and U-69593 was purchased from Sigma-Aldrich (Budapest, Hungary). Fatty acid free bovine serum albumin (BSA) was purchased from Serva (Heidelberg, Germany). The highly selective MOR agonist enkephalin analogue Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO), the highly selective DOR agonist Ile^{5,6}-deltorphin II (IleDelt II) was synthesized in the Laboratory of Chemical Biology group of the Biological Research Centre (BRC, Szeged, Hungary). The non-selective opioid receptor antagonist naloxone was kindly provided by the company Endo Laboratories DuPont de Nemours (Wilmington, DE, USA). WIN55 212–2 was purchased from Tocris Bioscience (Bristol, UK). Ligands were dissolved in water and were stored in 1 mM stock solution at -20 °C. The radiolabelled GTP analogue, [³⁵S]GTP γ S (specific activity: 1000 Ci/mmol) was purchased from Hartmann Analytic (Braunschweig, Germany). [³H]DAMGO (specific activity: 38.8 Ci/mmol), [³H]IleDelt II (specific activity: 19.6 Ci/mmol),¹⁸ and [³H]WIN55 212–2 (specific activity: 13.1 Ci/mmol) were radiolabeled by the Laboratory of Chemical Biology group in BRC (Szeged, Hungary). [³H]U-69593 (specific activity: 43.6 Ci/mmol) was purchased from Perkin Elmer (Perkin Elmer, Waltham, MA).

Animals

For membrane homogenate preparations male and female Wistar rats (250–300 g body weight) and male guinea pigs (~700 g body weight, LAL/HA/BR strain) were used. Rats were housed in the local animal house of BRC (Szeged, Hungary), while guinea pigs were housed in LAB-ÁLL Bt. (Budapest, Hungary). All the animals were kept in a temperature controlled room (21–24 °C) under a 12:12 light and dark cycle and were provided with water and food *ad libitum*. All housing and experiments were conducted according to the European Communities Council Directives (86/606/ECC) and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 32.§). The total number of animals as well as their suffering was minimized.

Rat and guinea pig brain membrane homogenate preparation for binding assays

Rats and guinea pigs were decapitated and their brains were quickly removed. The brains were prepared for membrane preparation according to Benyhe et al.²⁶ and partly used for binding experiments and partly were further prepared for the [³⁵S]GTP γ S binding experiments according to Zádor et al.²⁷. Briefly the brains were homogenized, centrifuged in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and incubated at 37 °C for 30 min in a shaking water-bath^{28–30}. After incubation the centrifugation was repeated as described before and the final pellet was suspended in 50 mM Tris-HCl pH 7.4 buffer containing 0.32 M sucrose, and stored at -80 °C. For the [³⁵S]GTP γ S binding experiments the final pellet of rat brain membrane homogenate was suspended in ice-cold TEM (Tris-HCl, EGTA, $MgCl_2$) and stored at -80 °C for further use.

Receptor binding assays

Radioligand competition binding experiments

Aliquots of frozen rat brain membrane homogenates were centrifuged (18 000 rpm, 20 min, 4 °C) to remove sucrose and the pellets were suspended in 50 mM Tris-HCl buffer (pH 7.4). Membranes containing 0.3–0.5 mg/ml of protein were incubated in the presence of unlabelled fentanyl and fentanyl analogues (OMDM584–595) in crescent concentrations (10^{-10} – 10^{-5} M) for 35 °C for 45 min with ~1 nM [³H]DAMGO in 35 °C for 45 min. OMDM585 and 586 (10^{-10} – 10^{-5} M) were also incubated with ~1 nM of [³H]IleDelt II, [³H]U-69593, or [³H]WIN55 212–2 in 30 °C for 30 min, in 24 °C for 45 min and in 30 °C for 60 min, respectively in rat brain homogenates, while in case of [³H]U-69593 in guinea pig brain membrane homogenates (the guinea pig brain has significantly more kappa receptors than the rat brain). Additionally, unlabeled IleDelt II, U-69593 and WIN55 212–2 were also incubated together with their labeled counterparts in increasing concentrations (10^{-10} – 10^{-5} M) for control.

For experiments performed with [³H]WIN55 212–2 the incubation mixture also contained 50 mM Tris/HCl, 2.5 mM EGTA, 5 mM $MgCl_2$ and 0.5 mg/ml fatty acid-free BSA (pH 7.4). The level of non-specific binding was determined in the presence of 10 μ M unlabelled naloxone or WIN55 212–2, while total binding was determined in the absence of cold compounds. The reaction was terminated by rapid filtration under vacuum (Brandel M24R Cell Harvester; Brandel Harvesters, Gaithersburg, MD), and washed thrice with 5 ml ice-cold 50 mM Tris-HCl or 50 mM Tris/HCl, 2.5 mM EGTA, 5 mM $MgCl_2$, 0.5% BSA (pH 7.4) in case of [³H]WIN55 212–2.

The filtration was accomplished through Whatman GF/C ([³H]DAMGO, [³H]IleDelt II or GF/B ([³H]U-69593 and [³H]WIN55 212–2) glass fibres (GE Healthcare, Little Chalfont, UK). In case of [³H]WIN55 212–2 the filter was pre-soaked in 0.1% polyethyleneimine 30 min before the filtration. The radioactivity of the filters was detected in UltimaGold™ MV aqueous scintillation cocktail (Perkin Elmer, Waltham, MA) with Packard Tricarb 2300TR liquid scintillation counter (Perkin Elmer, Waltham, MA). The competition binding assays were performed in duplicate and repeated at least three times.

Functional [³⁵S]GTP γ S binding experiments

In [³⁵S]GTP γ S binding experiments, we measure the GDP→GTP exchange of the $G_{\alpha i/o}$ protein in the presence of a given ligand to measure ligand potency and the maximal efficacy of receptors G-protein. The nucleotide exchange is monitored by a radioactive, non-hydrolysable GTP analogue, [³⁵S]GTP γ S.

The functional [³⁵S]GTPγS binding experiments were performed as previously described³¹, with modifications. Briefly the rat brain membrane homogenates containing ~10 μg/ml protein were incubated at 30 °C for 60 min in Tris-EGTA buffer (pH 7.4) composed of 50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl₂, 100 mM NaCl, containing 20 MBq/0.05 cm³ [³⁵S]GTPγS (0.05 nM) and increasing concentrations (10⁻¹⁰–10⁻⁵ M) of fentanyl and fentanyl analogues (**OMDM 584–595**) in the presence or absence of 10 μM naloxone and excess GDP (30 μM) in a final volume of 1 ml. Total binding was measured in the absence of test compounds, non-specific binding was determined in the presence of 10 μM unlabelled GTPγS. The bound and unbound [³⁵S]GTPγS was separated as described in the competition binding assays section through Whatmann GF/B glass fibres. The radioactivity of the filters was also detected as described above. [³⁵S]GTPγS binding experiments were performed in triplicates and repeated at least three times.

Data analysis

The specific binding of all radiolabeled compounds was calculated by the subtraction of non-specific binding from total binding and was given in percentage. Data were normalized to total specific binding, which was settled 100%, which in case of [³⁵S]GTPγS also represents the basal activity of the G-protein. Experimental data were presented as means ± SEM in the function of the applied ligand concentration range in logarithm form. Points were fitted with the professional curve fitting program, GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-linear regression. In the radioligand competition binding assays the ‘One-site competition’, while in [³⁵S]GTPγS binding assays the ‘Sigmoid dose-response’ equation was applied to determine IC₅₀ (unlabelled ligand affinity) and the maximum G-protein efficacy (E_{max}) and ligand potency (EC₅₀), respectively. For IC₅₀ and EC₅₀ values standard error is only given in their logarithm form by the curve fitting program due to the data representation. Statistical analyses were performed with GraphPad Prism 5.0. In case of two data sets, unpaired *t*-test with two-tailed *p* values statistical analysis was used, while for three or more data sets one-way ANOVA with Tukey’s multiple comparison tests were performed to determine the significance level. Since unlabelled ligand concentrations were presented in the logarithm form, the curve fitting programme could only calculate SEM. for the logarithm form of IC₅₀ (logIC₅₀) and EC₅₀ (logEC₅₀) values. At the same time their antilogarithm form has also been indicated. Significance was accepted at the *p* < 0.05 level.

Biochemical assays

Fatty acid amide hydrolase (FAAH) assays

The activity of products on the enzymatic hydrolysis of anandamide (AEA) was obtained using membranes prepared from rat brain, incubated with the test compounds and [¹⁴C] AEA (2.4 μM) in 50 mM Tris-HCl, pH 9, for 30 min at 37 °C. [¹⁴C]Ethanolamine produced from [¹⁴C]AEA hydrolysis was measured by scintillation counting of the aqueous phase after extraction of the incubation mixture with two volumes of CHCl₃/CH₃OH = 2/1 (by volume). Data were expressed as the concentration exerting 50% inhibition of AEA hydrolysis (IC₅₀), calculated by GraphPad.

Assay of MAGL activity

The 10 000 g cytosolic fraction from COS-7 cells was incubated in tris HCl 50 mM, at pH 7.0 at 37 °C for 20 min, with synthetic 2-[³H] arachidonoyl-glycerol (1.0 mCi/mmol, 25 mM). After incubation, lipids were extracted with two volumes of chloroform/methanol = 2/1 (by volume), and the extracts were lyophilized under vacuum. Extracts were fractionated by TLC on silica on

plastic plates using CHCl₃/MeOH/NH₄OH (85/15/1 by volume) as the eluting system. Bands corresponding to [³H]arachidonic acid were cut, and their radioactivity was counted with a β-counter.

In vivo nociception test

Animals

Male CD-1 mice (Harlan, Italy) weighing 25–30 g were used for all experiments. Mice were housed for at least 1 week before the experimental sessions in colony cages (7 mice in each cage) under standard light (from 7.00 a.m. to 7.00 p.m.), temperature (21 ± 1 °C), relative humidity (60 ± 10%) with food and water available *ad libitum*. The research protocol was approved by the Service for Biotechnology and Animal Welfare of the Istituto Superiore di Sanità and authorised by the Italian Ministry of Health, according to Legislative Decree 26/14, which implemented the European Directive 2010/63/UE on laboratory animal protection in Italy. Animal welfare was routinely checked by veterinarians from the Service for Biotechnology and Animal Welfare.

Surgery for intracerebroventricular (i.c.v.) injections

For i.c.v. injections, mice were lightly anaesthetized with isoflurane, and an incision was made in the scalp. Injections were performed using a 10 μl Hamilton microsyringe at a point 2-mm caudal and 2-mm lateral from the bregma at a depth of 3 mm in a volume of 5 μL as previously described³².

Hot-plate test

Thermal nociception (hot-plate test) was assessed with a commercially available apparatus consisting of a metal plate 25 × 25 cm (Ugo Basile, Italy) heated to a constant temperature of 55.0 ± 0.1 °C, on which a plastic cylinder (20 cm diameter, 18 cm high) was placed. The time of latency (s) was recorded from the moment the animal was placed in the cylinder on the hot plate until it licked its paws or jumped; the cut-off time was 60 s. The baseline was calculated as mean of three readings recorded before testing at intervals of 15 min, and was in the same order of magnitude in all experimental groups (mean 9.8 ± 1.2 s, *N* = 8–10). The time course of latency was then determined at 15, 30, 45 and 60 min after compound treatment. Experimental data were expressed as time course of the percentage of maximum effect (%MPE) = (post-drug latency – baseline latency)/(cut-off time–baseline latency) × 100. On each test day compound solutions were freshly prepared using DMSO:0.9% saline 1:5 v/v. These solutions were injected at a dose of 10 μg/mouse in a volume of 5 μL/mouse. The significance among the groups was evaluated with the analysis of variance followed by Tukey’s post-hoc comparisons using GraphPad Prism 6.03 software. Statistical significance was assumed at least for *p* < 0.05.

Acknowledgements

We are grateful to Prof. Giorgio Ortari and Prof. Enrico Morera (Department of Chemistry and Technology, ‘‘Sapienza’’ University of Rome) for their suggestions and mentoring activity.

Declaration of interest

This research was partly supported by an OTKA-108518 grant (S. Benyhe) provided by National Research, Development and Innovation Office (NKFIH), Budapest, Hungary.

References

- Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. *Exp Clin Psychopharmacol* 2008;16:405–16.
- (a) Vucković S, Prostran M, Ivanović M, et al. Pharmacological evaluation of 3-carbomethoxy fentanyl in mice. *Curr Med Chem*

- 2009;16:2468–74. (b) Casy AF, Parfitt RT. Opioid analgesics: chemistry and receptors. New York: Springer; 1986.
3. (a) Subramaniam A. Opioid ligands with mixed m/d opioid receptor interactions: an emerging approach to novel analgesics. *AAPS J* 2006;8:118–25. (b) van Rijn RM, DeFriel JN, Whistler JL. Pharmacological traits of delta opioid receptors: pitfalls or opportunities? *Psychopharmacology (Berl)* 2013;228:1–18. (c) Gomes I, Gupta A, Filipovska J, et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. *Proc Natl Acad Sci USA* 2004;101:5135–9.
 4. (a) Mollica A, Pinnen F, Feliciani F, et al. New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4,4' positions and non-hydrazine linkers. *Amino Acids* 2010;40:1503–11. (b) Mollica A, Pinnen F, Costante R, et al. Biological active analogues of the opioid peptide biphalin: mixed $\alpha/\beta(3)$ -peptides. *J Med Chem* 2013;56:3419–23. (c) Mollica A, Costante R, Stefanucci A, et al. Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker. *J Pept Sci* 2013;19:233–9. (d) Mollica A, Costante R, Novellino E, et al. Design, synthesis and biological evaluation of two opioid agonist and Cav 2.2 blocker multitarget ligands. *Chem Biol Drug Des* 2015; 86:156–62.
 5. (a) Petrov RR, Lee YS, Vardanyan RS, et al. Effect of anchoring 4-anilidopiperidines to opioid peptides. *Bioorg Med Chem Lett* 2013; 23:3434–7. (b) Podolsky AT, Sandweiss A, Hu J, et al. Novel fentanyl-based dual μ/δ -opioid agonists for the treatment of acute and chronic pain. *Life Sci* 2013;93:1010–6. (c) Deekonda S, Wugalter L, Rankin D, et al. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. *Bioorg Med Chem Lett* 2015; 25:4683–8.
 6. (a) Parker KE, McCall JG, McGuirk SR, et al. Effects of co-administration of 2-arachidonylglycerol (2-AG) and a selective μ -opioid receptor agonist into the nucleus accumbens on high-fat feeding behaviors in the rat. *Brain Res* 2015;1618:309–15. (b) Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. *Neuroscience* 2013;248:637–54.
 7. Dvoracko S, Stefanucci A, Novellino E, Mollica A. The design of multitarget ligands for chronic and neuropathic pain. *Future Med Chem* 2015;7:2469–83.
 8. (a) Ahn K, Johnson DS, Mileni M, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. *Chem Biol* 2009;16:411–20. (b) Karlsson J, Morgillo CM, Deplano A, et al. Interaction of the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and ibuprofen with FAAH: enantiomeric selectivity and binding mode. *PLoS One* 2015;10:e0142711.
 9. Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. *Expert Opin Drug Discov* 2009;4:763–84.
 10. a) Ligresti A, Morera E, Van Der Stelt M, et al. Further evidence for the existence of a specific process for the membrane transport of anandamide. *Biochem J* 2004;15:265–72. (b) Maione S, Morera E, Marabese I, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. *Br J Pharmacol* 2008;155:775–82. (c) Morera E, Petrocellis LD, Morera L, et al. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. *Bioorg Med Chem Lett* 2009;19:6806–9. (d) Gustin DJ, Ma Z, Min X, et al. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. *Bioorg Chem Chem Lett* 2011;21:2492–6.
 11. Jagerovic N, Fernández-Fernández C, Erdozain AM, et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. *Drug Des Devel Ther* 2014;8:263–77.
 12. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. *FEBS Lett* 1994;350:240–4.
 13. (a) Cinar R, Szücs M. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. *J Pharmacol Exp Ther* 2009;330: 567–74. (b) Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. *Biochem Pharmacol* 2012;83:260–8. (c) Zádor F, Kocsis D, Borsodi A, Benyhe S. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. *Neurochem Int* 2014;67:14–22.
 14. Lange JHM, Kruse CG. Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. *Drug Discov Today* 2005;10:693–702.
 15. Dosen-Micovic L, Ivanovic M, Micovic V. Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. *Bioorg Med Chem* 2006;14:2887–95.
 16. Jensen TS, Finnerup NB. Neuropathic pain treatment: a further step forward. *Lancet* 2009;374:1218–19.
 17. Mollica A, Stefanucci A, Costante R, Hruby VJ. Rational approach to the design of bioactive peptidomimetics: recent developments in opioid agonist peptides. Elsevier; 2014, p. 27.
 18. (a) Vardanyan RS, Hruby VJ. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. *Future Med Chem* 2014;6:385–412. (b) Joja E, Tourwé D, Kertész I, et al. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity. *Brain Res Bull* 2007;74:119–29.
 19. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. *J Mol Biol* 1993;234:779–815.
 20. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J Comput Chem* 2010;31:455–61.
 21. Sanner FM Python: a programming language for software integration and development. *J Mol Graph Model* 1999;17:57–61.
 22. Hanwell MD, Curtis DE, Lonie DC, et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. *J Cheminform* 2012;4:17.
 23. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph* 1996;14:33–8.
 24. Sanner MF, Spehner J-C, Olson AJ. Reduced surface: an efficient way to compute molecular surfaces. *Biopolymers* 1996;38:305–20.
 25. R Development Core Team (2008); R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available from: <http://www.R-project.org>.
 26. Benyhe S, Farkas J, Tóth G, Wollemann M. Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. *J Neurosci Res* 1997;48:249–58.
 27. Zádor F, Kocsis D, Borsodi A, Benyhe S. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. *Neurochem Int* 2014;67:14–22.
 28. Sim LJ, Selley DE, Childers SR. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. *Proc Natl Acad Sci USA* 1995;92:7242–6.
 29. Traynor JR, Nahorski SR. Modulation by m-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. *Mol Pharmacol* 1995; 47:848–54.
 30. Foran SE, Carr DB, Lipkowski AW, et al. Inhibition of morphine tolerance development by a substance P-opioid peptide chimera. *J Pharmacol Exp Ther* 2000;295:1142–8.
 31. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. *Physiol Behav* 1976;17:1031–6.
 32. Porreca F, Mosberg HI, Hurst R, et al. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. *J Pharmacol Exp Ther* 1984;230:341–8.